Cognitive-Motor Training for Gait Adaptability in Parkinson Disease
NCT07907718, Not applicable, Not yet recruiting, National Yang Ming Chiao Tung University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cognitive-Motor Training for Gait Adaptability in Parkinson Disease | ClinicalTrials.gov |
| NCT number | NCT07907718 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | National Yang Ming Chiao Tung University | ClinicalTrials.gov |
| Conditions | Parkinson Disease | ClinicalTrials.gov |
| Interventions | Cognitive-motor training, Conventional physiotherapy | ClinicalTrials.gov |
| First posted | 2026-10-30 | ClinicalTrials.gov |
| Last updated | 2026-10-30 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Gait speed | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Gait speed during obstacle crossing was measured using the GAITRite system. Continuous obstacle-crossing walking performance was assessed using the GaitUp system. | ClinicalTrials.gov |
| Primary | Step length | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Using GAITRite system to measure step length | ClinicalTrials.gov |
| Primary | Step width | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Using GAITRite system to measure step width | ClinicalTrials.gov |
| Primary | Single support time | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Using GAITRite system to measure single support time | ClinicalTrials.gov |
| Primary | Gait Variability | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Gait variability during continuous obstacle crossing will be assessed using the GaitUp system and expressed as the coefficient of variation (CV = standard deviation / mean × 100%) of step time and stride length. | ClinicalTrials.gov |
| Primary | Stride length | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Using the GaitUp system to measure stride length during continuous obstacle-crossing walking. | ClinicalTrials.gov |
| Primary | Swing phase | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Using the GaitUp system to measure swing phase during continuous obstacle-crossing walking. | ClinicalTrials.gov |
| Primary | Four Square Step Test | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | The Four Square Step Test is a test used to assess the ability to step over objects and measures the time in seconds to navigate all four squares. | ClinicalTrials.gov |
| Primary | Event-related potential - N2 | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Measure event-related potential through electroencephalography during the Go/No-go test | ClinicalTrials.gov |
| Primary | Event-related potential - P300 | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Measure event-related potential through electroencephalography during the Go/No-go test | ClinicalTrials.gov |
| Primary | Stroop color and word test | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Record numbers of corrected color words which the subject responds within 45 sec. | ClinicalTrials.gov |
| Primary | Trail making test | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Trail making test contain part A and part B. Faster completing the test indicates better executive function. | ClinicalTrials.gov |
| Secondary | Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Motor symptoms will be assessed using Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Scores range from 0 to 132, with higher scores indicating greater motor impairment. | ClinicalTrials.gov |
| Secondary | Single-Leg Standing Balance | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Balance will be assessed by measuring the time, in seconds, that participants can stand on one leg. Longer standing times indicate better balance. | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment | Before and after 8 weeks of intervention, as well as 4 weeks after intervention | Montreal Cognitive Assessment ranges from 0 to 30. Higher scores reflect better cognitive performances. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Go/No-Go Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)